title: [Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
abstract: OBJECTIVE
  To assess the cost-effectiveness of chemotherapy for patients with non-resectable pancreatic cancer, we compared two regimens containing either gemcitabine (GEM) or S-1.
  
  
  METHODS
  We developed a decision tree that showed the clinical processes of non-resectable pancreatic cancer patients. We calculated the probabilities of endpoint and life months gained (LMG) based on previously reported articles. To estimate the costs, we analyzed medical records of 44 inpatients with non-resectable pancreatic cancer treated with GEM(n=34)or S-1(n=10). Sensitivity analysis was used to check the robustness of the results.
  
  
  RESULTS
  In the GEM group and S-1 group, costs were 1,636,393 and 985,042 yen, and LMG was 6. 0 and 9. 0 months, respectively. Thus, the cost-effectiveness ratio(CER)was calculated to be 272,732 and 109,449 yen/LMG, respectively, and the incremental cost effectiveness ratio (ICER) was -217,117 yen/LMG. The sensitivity analysis showed that the result was definitely robust.
  
  
  CONCLUSIONS
  Our findings suggest that the markedly cost-effective S-1 regimen could prolong LMG with less cost than the GEM regimen.
authors.affiliation: Department of Pathophysiology, School of Pharmacy, Showa University.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kurihara
authors.forename: Mariko
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Mari
authors.initials: M
authors.lastname: Kogo
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Yoneyama
authors.forename: Nanako
authors.initials: N
authors.lastname: Ito
authors.forename: Tomiko
authors.initials: T
authors.lastname: Sunaga
authors.forename: Kazuo
authors.initials: K
authors.lastname: Konishi
authors.forename: Michio
authors.initials: M
authors.lastname: Imawari
authors.forename: Takashi
authors.initials: T
authors.lastname: Tobe
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kiuchi
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000191:economics* / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000473:pathology; D005641:Tegafur / Q000191:economics* / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine